Stockscreener 앱 받기
2.28
1.72%
-0.04
시간 외 거래:
2.28
전일 마감가:
$2.32
열려 있는:
$2.32
하루 거래량:
137.56K
Relative Volume:
0.94
시가총액:
$91.91M
수익:
$2.70M
순이익/손실:
$5.53M
주가수익비율:
20.73
EPS:
0.11
순현금흐름:
$-10.55M
1주 성능:
-4.60%
1개월 성능:
-2.98%
6개월 성능:
-11.28%
1년 성능:
+4.59%
1일 변동 폭
$2.27
$2.36
1주일 범위
$2.27
$2.41
52주 변동 폭
$2.00
$3.67
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
명칭
Oramed Pharmaceuticals Inc
전화
646-844-1164
주소
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
ORMP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
2.28 | 91.91M | 2.70M | 5.53M | -10.55M | 0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-01-12 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-04-20 | 개시 | Canaccord Genuity | Buy |
| 2021-02-09 | 개시 | National Securities | Buy |
| 2020-12-03 | 개시 | Alliance Global Partners | Buy |
| 2020-03-11 | 개시 | Aegis Capital | Buy |
| 2019-09-11 | 개시 | Ladenburg Thalmann | Buy |
| 2017-12-11 | 재개 | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | 재확인 | FBR Capital | Outperform |
| 2015-12-01 | 재확인 | H.C. Wainwright | Buy |
| 2015-11-19 | 개시 | FBR Capital | Outperform |
| 2015-04-13 | 재개 | MLV & Co | Buy |
| 2014-01-30 | 재확인 | Aegis Capital | Buy |
| 2014-01-08 | 재확인 | Aegis Capital | Buy |
| 2014-01-08 | 개시 | MLV & Co | Buy |
| 2013-12-03 | 개시 | Aegis Capital | Buy |
모두보기
Oramed Pharmaceuticals Inc 주식(ORMP)의 최신 뉴스
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Significant Decrease in Short Interest - MarketBeat
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to “Hold” at StockNews.com - Defense World
Oramed Pharmaceuticals (NASDAQ:ORMP) Raised to Hold at StockNews.com - MarketBeat
Oramed Pharmaceuticals Reports Deferral and Consent Agreement for Tranche B Senior Secured Convertible Note - Defense World
Oramed Pharmaceuticals (NASDAQ:ORMP) Lowered to Sell Rating by StockNews.com - MarketBeat
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.com - Defense World
ADVANZ PHARMA (OTCMKTS:CXRXF) versus Oramed Pharmaceuticals (NASDAQ:ORMP) Critical Comparison - Defense World
Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Increased to Hold at StockNews.com - MarketBeat
StockNews.com Upgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to “Hold” - Defense World
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to Hold at StockNews.com - MarketBeat
Oramed secures $13.2 million payment from Scilex - Investing.com
Oramed secures $13.2 million payment from Scilex By Investing.com - Investing.com UK
Palo Alto pharmaceutical company secures $17M - The Business Journals
Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation - The Manila Times
Scilex Holding Company Announces Early Installment Payment - GlobeNewswire
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - The Eastern Progress Online
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Above 50 Day Moving AverageHere's What Happened - MarketBeat
ORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent Agreements - Yahoo Finance
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Below 200-Day Moving AverageTime to Sell? - MarketBeat
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Stock Holdings Lifted by BML Capital Management LLC - MarketBeat
Oramed Pharmaceuticals : INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTSAS OF SEPTEMBER 30, 2024 - Marketscreener.com
Type 1 Diabetes Market Future Business Opportunities 2024-2031 - openPR
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat
US Penny Stocks To Watch: 3 Picks With Market Caps Over $40M - Simply Wall St
Some of the Major Key Players in the oral proteins and peptides market are - InsightAce Analytic
Oramed Announces Additional $1M Payment on Tranche A Note By Investing.com - Investing.com South Africa
Oramed Announces Additional $1M Payment on Tranche A Note - Investing.com India
Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Increased to Buy at StockNews.com - MarketBeat
Oramed Pharmaceuticals (NASDAQ:ORMP) Cut to "Hold" at StockNews.com - MarketBeat
ORAMED PHARMACEUTICALS INC. Refinances with New Securities Purchase Agreement - MarketBeat
Oramed Pharmaceuticals Reinforces Scilex Financial Ties - TipRanks
Scilex Holding extends payment deadline in Oramed agreement - Investing.com India
Scilex Holding Company Announces Signing of a $50 Million - GlobeNewswire
Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile - Yahoo Finance
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to Buy by StockNews.com - MarketBeat
Tranche Update on Oramed Pharmaceuticals Inc.'s Equity Buyback Plan announced on June 26, 2024. - Marketscreener.com
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares Bought by Murchinson Ltd. - MarketBeat
Oramed signs $11.5 million deal for clinical trial services By Investing.com - Investing.com South Africa
Oramed signs $11.5 million deal for clinical trial services - Investing.com
Non-Alcoholic Steatohepatitis Pipeline Insights 2024: - openPR
Non-Alcoholic Steatohepatitis Pipeline Insights 2024: Therapies, Clinical Trials, and MOA, ROA by DelveInsight | Viking Therapeutics, Seal Rock Therapeutics, AstraZeneca, Boehringer Ingelheim, Oramed - Barchart
Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded by StockNews.com to Hold - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) and Oramed Pharmaceuticals (NASDAQ:ORMP) Financial Review - Defense World
Murchinson Ltd. Trims Stock Holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - MarketBeat
Scilex Holding agrees to payment terms with Oramed Pharmaceuticals - Investing.com India
Oramed Pharmaceuticals (ORMP) Price Target Increased by 57.50% to 3.21 - MSN
Moors & Cabot Inc. Buys 164 Shares of O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World
Oriole Resources (LON:ORR) Shares Down 2.3% - Defense World
Oramed Pharmaceuticals Inc (ORMP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.65%
4.62%
자본화:
|
볼륨(24시간):